The Technical AnalystExchange: EURONEXT Sector: Healthcare Industry: Biotechnology
Pharma Mar, S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.32% €36.72
America/New_York / 17 mai 2024 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 655.05 mill |
| EPS: | 0.110 |
| P/E: | 333.82 |
| Earnings Date: | Jul 25, 2024 |
| SharesOutstanding: | 17.84 mill |
| Avg Daily Volume: | 0.0416 mill |
| RATING 2024-05-17 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 19.55x |
| Company: PE 333.82 | sector: PE 17.08 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 333.82 | industry: PE -7.48 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€83.64 (127.77%) €46.92 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
€ 35.81 - 37.63 ( +/- 2.48%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €36.72 (1.32% ) |
| Volume | 0.0429 mill |
| Avg. Vol. | 0.0416 mill |
| % of Avg. Vol | 103.29 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PHM.MC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PHM.MC
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.